Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with <i>BRCA1/2</i>- and Non-<i>BRCA1/2</i>-Mutant Cancers.

导出 OA

翻译打印收藏纠错

作者： Timothy A,Yap ^[1] ; Rebecca,Kristeleit ^[2] ; Vasiliki,Michalarea ^[3] ; Stephen J,Pettitt ^[4] ; Joline S J,Lim ^[5] ; Suzanne,Carreira ^[6] ; Desamparados,Roda ^[4] ; Rowan,Miller ^[2] ; Ruth,Riisnaes ^[4] ; Susana,Miranda ^[2] ; Ines,Figueiredo ^[3] ; Daniel Nava,Rodrigues ^[2] ; Sarah,Ward ^[2] ; Ruth,Matthews ^[2] ; Mona,Parmar ^[2] ; Alison,Turner ^[4] ; Nina,Tunariu ^[2] ; Neha,Chopra ^[4] ; Heidrun,Gevensleben ^[2] ; Nicholas C,Turner ^[4] ; Ruth,Ruddle ^[2] ; Florence I,Raynaud ^[4] ; Shaun,Decordova ^[2] ; Karen E,Swales ^[4] ; Laura,Finneran ^[4] ; Emma,Hall ^[5] ; Paul,Rugman ^[2] ; Justin P O,Lindemann ^[4] ; Andrew,Foxley ^[5] ; Christopher J,Lord ^[2] ; Udai,Banerji ^[2] ; Ruth,Plummer ^[2] ; Bristi,Basu ^[2] ; Juanita S,Lopez ^[2] ; Yvette,Drew ^[2] ; Johann S,de Bono ^[7]

作者单位： Royal Marsden Hospital, London, United Kingdom. tyap@mdanderson.org. ^[1] The Institute of Cancer Research, London, United Kingdom. ^[2] University College London, London, United Kingdom. ^[3] Royal Marsden Hospital, London, United Kingdom. ^[4] The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom. ^[5] The CRUK Gene Function Laboratory, The Institute of Cancer Research, London, United Kingdom. ^[6] Oncology R&D, AstraZeneca, Cambridge, United Kingdom. ^[7] Clinical and Translational Research Institute, Newcastle University, Newcastle, United Kingdom. ^[8] Department of Oncology, University of Cambridge, Cambridge, United Kingdom. ^[9]